Table 1.
Log gene copies per gram wet feces |
SE4 |
P < |
|||||||
---|---|---|---|---|---|---|---|---|---|
Control1 | Subtherapeutic2 | Therapeutic3 | Trt | Breed | Gender | Day | Interactions5 | ||
n | 12 | 7 | 9 | ||||||
tetG | 7.40 | 7.29 | 7.17 | 0.18 | NS | NS | NS | 0.06 | Trt*gender; breed*gender |
tetO | 9.18 | 9.10 | 9.13 | 0.34 | NS | NS | NS | NS | NS |
tetW | 8.89 | 8.80 | 8.43 | 0.28 | NS | NS | NS | 0.07 | NS |
tetX | 7.47 | 7.70 | 6.99 | 0.34 | NS | NS | NS | NS | NS |
sul1 | 6.29 | 5.88 | 6.34 | 0.28 | NS | 0.10 | NS | NS | Trt*gender; gender*week |
sul2 | 6.78 | 6.64 | 6.61 | 0.23 | NS | NS | NS | NS | NS |
ermB | 7.20 | 7.31 | 6.82 | 0.37 | NS | NS | NS | NS | NS |
ermF | 7.91 | 7.36 | 6.95 | 0.32 | 0.04 | NS | NS | 0.003 | NS |
1Control milk replacer containing no antibiotics fed from day 2 to weaning (59 ± 2 day).
2Medicated milk replacer containing 10 mg/calf/day of tetracycline and neomycin fed from day 2 to weaning.
3Medicated milk replacer containing 1000 mg/calf/day of tetracycline and neomycin fed from day 36 to weaning.
4SE for treatment LS means.
5Significant (P < 0.10) two and three way interactions of treatment, breed, gender, and week.